Merck and Daiichi Pull US Lung Cancer Therapy Bid
Merck and Daiichi Sankyo have withdrawn their US application for an experimental lung cancer therapy following discussions with regulators. The FDA determined that mid-stage trial data did not meet requirements for accelerated approval. The companies plan to continue evaluating the treatment in larger late-stage trials.
Xurve View
Insights:
Xurve View
Merck and DAIICHI SANKYO CO LTD withdrew their United States application seeking accelerated approval for an experimental lung cancer therapy. The decision marks the second setback under their $22B cancer partnership.
